Clinical Imaging and Immunotherapy in Cancer Research
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 12
Special Issue Editor
Special Issue Information
Dear Colleagues,
The intersection of clinical imaging and immunotherapy has emerged as a transformative frontier in cancer research. As immunotherapy reshapes the landscape of cancer treatment by harnessing the body's immune system to target tumors, advanced imaging techniques play a critical role in evaluating therapeutic responses, monitoring disease progression, and guiding clinical decision-making. Modalities such as PET, MRI, and CT scans provide non-invasive insights into the tumor microenvironment, enabling the visualization of immune cell infiltration, metabolic changes, and biomarker expression. Moreover, the integration of molecular imaging with immunotherapeutic strategies facilitates real-time assessment of treatment efficacy and the early detection of resistance or adverse events. This synergistic approach not only enhances the precision of cancer diagnosis and prognosis but also supports the development of personalized treatment regimens. As research continues to evolve, clinical imaging stands poised to be an indispensable tool in optimizing and advancing immunotherapy outcomes in oncology.
Dr. Fabio Sandomenico
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- immune checkpoint inhibitors
- molecular imaging
- tumor microenvironment
- artificial intelligence (AI)
- radiomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
